# Content Changelog
The following changes have been made to the content catalogued within the Molecular Oncology Almanac knowledge base.

## December 2022 release
In this release, we have removed neoantigen burden as a cataloged feature type and combined Silencing with Knockdown feature types. 

Added entries:
- (FDA) _RET_ fusions and sensitivity to selpercatinib in any solid tumor.

Revised entries:
- (Preclinical) _PPARGC1A_ knockdown with CRSPR-Cas9 and not favorable prognosis in melanoma was changed from the feature type Silencing to Knockdown.
- (Preclinical) _USP11_ knockdown with siRNA and sensitivity to olaparib in osteosarcoma was changed from the feature type Silencing to Knockdown.

Removed entries:
- (Clinical evidence) High Neoantigen Burden and sensitivity to pembrolizumab in non-small cell lung cancer.

## October 2022 release
Added entries:
- (FDA) _FGFR2_ rearrangements and sensitivity to futibatinib in intrahepatic cholangiocarcinoma.

Revised entries:
- (Clinical evidence) _SPOP_ variants and favorable prognosis in prostate adenocarcinoma was changed to sensitivity to abiraterone. Additionally, the doi url was revised to correctly point to the citation.

## September 2022 release
Added entries:
- (FDA) _FGFR1_ rearrangements and sensitivity to pemigatinib in myeloid/lymphoid neoplasms.

## August 2022 release
Added entries:
- (FDA) _ALK-EML4_ and sensitivity to crizotinib in inflammatory myofibroblastic tumors.
- (Clinical trial) _BRCA1_ and _BRCA2_ germline variants and sensitivity to olaparib.  
- (Clinical evidence) _BRCA2_ copy number deletion and loss-of-function somatic variants and sensitivity to olaparib in uterine leiomyosarcoma.
- (Clinical evidence) _CDKN2A_ deletion and sensitivity to palbociclib in uterine leiomyosarcoma.
- (Clinical evidence) _MYOCD_ amplification as a diagnostic for strong smooth muscle differentiation in leiomyosarcoma.
- (Preclinical) _RB1_ copy number deletion and somatic variants and sensitivity to olaparib and talazoparib in prostate cancer.
- (Preclinical) _RB1_ knockout and resistance to palbociclib in prostate cancer.
- (Preclinical) _USP11_ silencing and sensitivity to olaparib in osteosarcoma.
- (Inferential) _ATRX_ copy number deletions and poor prognosis in leiomyosarcoma. 
- (Inferential) _BRCA1_ and _BRCA2_ copy number deletion and loss-of-function somatic variants and sensitivity to PARP inhibition (KU0058684, KU0058948).
- (Inferential) _CDKN2C_ deletion may confer sensitivity to CDK4/6 inhibitors. 
- (Inferential) _MAP2K4_ and _MAPK7_ copy number amplification and not sensitive to chemotherapy as well as poor prognosis in osteosarcoma.  
- (Inferential) _PDGFRA_ copy number amplification and poor prognosis in breast cancer.
- (Inferential) _PTEN_ copy number deletion and poor prognosis in uterine leiomyosarcoma. 
- (Inferential) _PTEN_ copy number deletion and sensitivity to sapanisertib in combination with alpelisib in uterine leiomyosarcoma. 

## July 2022 release
Added entries:
- (FDA) _BRAF_ p.V600E and sensitivity to dabrafenib in combination with trametinib in any solid tumor.
- (FDA) _IDH1_ p.R132C, p.R132H and sensitivity to ivosidenib either in combination with azacitidine or as a monotherapy in acute myeloid leukemia.
- (FDA) MSI-H and sensitivity to pembrolizumab in endometrial carcinoma.

## March 2022 release
Revised entries:
- (FDA) _KRAS_ p.G12C and sensitivity to sotorasib's description was revised to remove underscores.
- (Preclinical) _KRAS_ somatic variants and sensitivity to FGFR1 inhibitor + trametinib was revised to remove a trailing space from the therapy name.

## November 2021 release
Added entries:
- (FDA) _BCR-ABL1_ and sensitivity to asciminib in chronic phase chronic myeloid leukemia. 
- (Clinical evidence) _SPOP_ missense somatic variants and favorable prognosis in de-novo metastatic castration-sensitive prostate cancer. 
- (Clinical evidence) _SPOP_ missense somatic variants and sensitivity to abiraterone in metastatic castration-resistant prostate cancer
- (Clinical evidence) _SPOP_ missense somatic variants and sensitivity to anti-androgen therapy.
- (Inferential) _CD274_ amplification and sensitivity to atezolizumab in non-small cell lung cancer. 

Revised entries:
- (FDA) _FGFR2_ fusions and sensitivity to erdafitnib's description was revised to match the standard's described in our [S.O.P.](https://github.com/vanallenlab/moalmanac-db/blob/main/docs/sop.md).

## October 2021 release
Added entries:
- (FDA) _EGFR_ exon 20 insertion variants and sensitivity to mobocertinib in non-small cell lung cancer.

Revised entries:
- (FDA) _BRCA1/2_ pathogenic germline variants and sensitivity to talazoparib was revised to properly cite the package insert and correct a spelling error in the description.
- (FDA) _BCR_-_ABL1_ and sensitivity to bosutinib in chronic myelogenous leukemia was revised to update the hyperlink for the package insert.
- (FDA) _BRAF_ p.V600E and sensitivity to encorafenib in melanoma was revised to update the hyperlink for the package insert. 
- (FDA) TMB-High and sensitivity to pembrolizumab in any solid tumor was revised to correct a spelling error in the description.

## September 2021 release
Added entries:
- (FDA) _IDH1_ p.R132C, p.R132H and sensitivity to ivosidenib in acute myeloid leukemia and cholangiocarcinoma.
- (FDA) _IDH1_ somatic variants and sensitivity to ivosidenib in acute myeloid leukemia and cholangiocarcinoma.
- (FDA) _PDGFRA_ p.D842V and sensitivity to avapritinib in gastrointestinal stromal tumors. 
- (Preclinical) _KIT_ p.D816V and sensitivity to avapritinib in gastrointestinal stromal tumors.
- (Preclinical) _KIT_ exon 11 and 17 somatic variants and sensitivity to avapritinib in gastrointestinal stromal tumors.
- (Preclinical) _KIT_ somatic variants and sensitivity to avapritinib in mast cell leukemia.   
- (Preclinical) _PDGFRA_ p.D842V and sensitivity to avapritinib in gastrointestinal stromal tumors.
- (Preclinical) _PDGFRA_ exon 18 somatic variants and sensitivity to avapritinib in gastrointestinal stromal tumors

Revised entries:
- (Guideline) _PDGFRA_ p.842V and sensitivity to imatinib was revised to not sensitive.  

## June 2021 release
Added entries:
- (FDA) _EGFR_ exon 20 insertion somatic variants and sensitivity to amivantamab-vmjw in metastatic non-small cell lung cancer.
- (FDA) _FGFR2_ fusions and sensitivity to infigratinib in cholangiocarcinoma.
- (FDA) _KRAS_ p.G12C and sensitivity to sotorasib in non-small cell lung cancer.

## May 2021 release
Added entries:
- (FDA) _ERBB2_ amplifications and sensitivity to pembrolizumab in combination with fluoropyrimidine, trastuzumab, and platinum-based chemotherapy in gastric or gastroesophageal junction adenocarcinoma.
- (Inferential) _CD274_ amplifications and sensitivity to pembrolizumab in gastric or gastroesophageal junction adenocarcinoma.

Revised entries:
- (Clinical evidence) _NF1_ germline variants associated with radiation therapy was not labeled with a clinical assertion. "1" has been set for adverse_event_risk.
- (Inferential) _ERBB2_ amplification and sensitivity to trastuzumab was changed to an inferential assertion from FDA. The description was also updated for these entries.

## February 2021 release
In addition to the content changes listed below, this release added a therapeutic strategy (`therapy_strategy`) for all sensitive and resistance relationships. 

Added entries:
- (FDA) _EGFR_ p.L858R and sensitivity to osimertinib in non-small cell lung cancer.
- (FDA) _EGFR_ exon 19 deletions and sensitivity to osimertinib in non-small cell lung cancer.
- (FDA) HER2-positive breast cancer and sensitivity to margetuximab-cmkb + chemotherapy. 

Revised entries:
- (Guideline) _ABL1_ p.T315I suggesting sensitivity to Omacetaxine in CML has been recategorized from a targeted therapy to chemotherapy.
- (Guideline) MSI-High associated with resistance to 5-Fluorouracil in colorectal adenocarcinoma. 5-Fluorouracil was reclassified as a chemotherapy therapy type instead of targeted therapy.
- (Guideline) _TET2_ somatic variants suggesting sensitivity to azacitidine was changed from a targeted therapy to chemotherapy.
- (Clinical evidence) _PAK1_ amplifications associated with poor prognosis in breast cancer. Removed Tamoxifen from this association as it is not asserting therapeutic sensitivity or resistance.
- (Preclinical) _KRAS_ somatic variants associated with sensitivity to trametinib + fgfr1 inhibition. Recorded therapy name to be alphabetical and changed inhibitor to be lowercase.
- (Preclinical) _RUNX1_--_RUNX1T1_ fusions and sensitivity to azacitidine + panobinostat has been reclassified as a combination therapy from targeted therapy. 

Mutational signature version has been added as a feature definition for mutational signatures. All catalogued assertions of this feature type are currently using Mutational Signatures (v2).

Several assertions from clinical guideline sources for multiple myeloma and myelodysplasia were incorrectly reported as clinical evidence. These have been updated to be guidelines.

Removed entries:

## December 2020 release
Added entries:
- (FDA) _RET_ somatic variants associated with sensitivity to pralsetinib in advanced or metastatic medullary thyroid cancer. 
- (FDA) _RET_ fusions associated with sensitivity to pralsetinib in advanced or metastatic thyroid cancer.
- (Inferential) _CDK274_ amplifications associated with sensitivity to chemotherapy in combination with pembrolizumab in locally recurrent or metastatic triple-negative breast cancer.

Revised entries:
- (Guideline) _CDK4_ amplifications associated with sensitivity to palbociclib in well-differentiated and dedifferentiated liposarcoma, updated source. 
- (Guideline) _KIT_ somatic variants associated with sensitivity to sunitinib in thymic carcinomas, updated source. 

Removed entries:
- (Preclinical) _CDKN2B_ deletions associated with sensitivity to EPZ015666.

## November 2020 release
This release focuses on FDA approvals since March 2020. In addition to the following changes, the citation style for all FDA approved associated have been updated to match [American Medical Association (AMA) style formatting](https://mdanderson.libanswers.com/faq/26246).

Added entries:
- (FDA) _ATM_ somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
- (FDA) _BARD1_ somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
- (FDA) _BRAF_ p.V600K, p.V600E associated with sensitivity to encorafenib in melanoma.
- (FDA) _BRAF_ p.V600E associated with sensitivity to cetuximab + encorafenib in colorectal cancer. 
- (FDA) _BRCA1_ and _BRCA2_ somatic and germline variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
- (FDA) _BRCA1_ and _BRCA2_ somatic and germline variants associated with sensitivity to niraparib in ovarian, fallopian tube, and peritoneal cancer.
- (FDA) _BRCA1_ and _BRCA2_ somatic variants associated with sensitivity to bevacizumab and olaparib in advanced ovarian, fallopian tube, and peritoneal cancer. 
- (FDA) _BRIP1_ somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
- (FDA) _CD274_ copy number amplifications associated with sensitivity to atezolizumab in non-small cell lung cancer. 
- (FDA) _CDK12_ somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
- (FDA) _CHEK1_ and _CHEK2_ somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
- (FDA) _ERBB2_ copy number amplifications associated with sensitivity to capecitabine + trastuzumab + tucatinib in breast cancer. 
- (FDA) _ERBB2_ copy number amplifications associated with sensitivity to chemotherapy + hyaluronidase-zzxf + pertuzumab + trastuzumab in breast cancer.
- (FDA) _ERBB2_ copy number amplifications associated with sensitivity to docetaxel + hyaluronidase-zzxf + pertuzumab + trastuzumab in metastatic breast cancer.
- (FDA) _EZH2_ p.Y646*, p.Y646F, p.Y646N, p.A682G, and p.A692V associated with sensitivity to tazemetostat in relapsed or refractory follicular lymphoma. 
- (FDA) _FANCL_ somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
- (FDA) _FGFR2_ fusions associated with sensitivity to pemigatinib in cholangiocarcinoma. 
- (FDA) High-TMB (> 10 coding mutations per Mb) associated with sensitivity to pembrolizumab in any unresectable or metastatic solid tumor.
- (FDA) _MET_ somatic splice site, deletion, and nonsense variants associated with sensitivity to capmatinib and crizotinib in non-small cell lung cancer.
- (FDA) _PALB2_ somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
- (FDA) _RAD51B_, _RAD51C_, _RAD51D_, and _RAD51L_ somatic variants associated with sensitivity to olaparib in metastatic castration-resistant prostate cancer.
- (FDA) _RET_ fusions associated with sensitivity to pralsetinib in non-small cell lung cancer.
- (FDA) _RET_ somatic variants associated with sensitivity to selpercatinib in medullarly thyroid cancer.
- (FDA) _RET_ fusions associated with sensitivity to selpercatinib in non-small cell lung cancer and thyroid cancer.
- (Inferential) COSMIC Signature 3, associated with Homologous Recombination Deficiency (HRD), associated with sensitivity to bevacizumab and olaparib in advanced ovarian, fallopian tube, and peritoneal cancer. 

Revised entries:
- (Clinical trial) _ATM_ frameshift, nonsense, and splice site somatic variants associated with sensitivity to BAY1895344 in any solid tumor. Updated disease context from "Advanced metastatic" to "Advanced or metastatic".
